|
NUP210 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.19310000054907E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.14120000011187E-07 |
| Normal-vs-Stage2 |
2.28139995783749E-09 |
| Normal-vs-Stage3 |
7.34679994618403E-09 |
| Normal-vs-Stage4 |
1.32709999989267E-07 |
| Stage1-vs-Stage2 |
6.056900E-03 |
| Stage1-vs-Stage3 |
2.871700E-02 |
| Stage1-vs-Stage4 |
3.089400E-01 |
| Stage2-vs-Stage3 |
5.264200E-01 |
| Stage2-vs-Stage4 |
3.539800E-01 |
| Stage3-vs-Stage4 |
6.391200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02480000041538E-07 |
| Normal-vs-AfricanAmerican |
2.13850000041482E-07 |
| Normal-vs-Asian |
1.26630000041317E-07 |
| Caucasian-vs-AfricanAmerican |
4.553800E-01 |
| Caucasian-vs-Asian |
6.414400E-01 |
| AfricanAmerican-vs-Asian |
7.567800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.89120000349786E-08 |
| Normal-vs-Female |
4.37520000229341E-08 |
| Male-vs-Female |
9.552000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.14609999952209E-07 |
| Normal-vs-Age(41-60Yrs) |
2.81239997956817E-09 |
| Normal-vs-Age(61-80Yrs) |
2.47170000022834E-07 |
| Normal-vs-Age(81-100Yrs) |
9.327700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.383600E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.456000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.601000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.847800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.320800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.989800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.302190E-01 |
| Classical-VS-Follicular |
4.918100E-02 |
| Classical-VS-Other |
5.513700E-02 |
| Classical-VS-Normal |
1.89260000005298E-07 |
| Tall-VS-Follicular |
6.364600E-01 |
| Tall-VS-Other |
6.671800E-01 |
| Tall-VS-Normal |
4.93049999716888E-08 |
| Follicular-VS-Other |
4.426800E-01 |
| Follicular-VS-Normal |
8.97469998317746E-09 |
| Other-VS-Normal |
4.02089999962385E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.32430000193895E-08 |
| Normal-vs-N1 |
1.22239995903328E-09 |
| N0-vs-N1 |
7.161600E-02 |
|
|
